Company to Host Conference Call On February 28, 2008 At 4:30 p.m. ET
PRINCETON, N.J., Feb. 21, 2008 (PRIME NEWSWIRE) -- Barrier Therapeutics, Inc. (Nasdaq:BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, will release fourth quarter and full year 2007 financial results on Thursday, February 28, 2008 at approximately 4:00 p.m. ET. The company will host a conference call that day at 4:30 p.m. ET to provide a company update and discuss the financial results for the quarter.
Conference call details:
Date: Thursday, February 28, 2008
Time: 4:30 p.m. ET
Dial-in: 888-680-0894 (U.S.)
617-213-4860 (International)
Conference ID code: 87131116
Web cast: http://www.barriertherapeutics.com (Investor Relations
section)
An audio replay of the call will be available for seven days:
Access: 888-286-8010 (U.S.)
617-801-6888 (International)
Replay Passcode: 21386961
About Barrier Therapeutics
Barrier Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of products in the field of dermatology. Barrier Therapeutics currently markets three pharmaceutical products in the United States: Xolegel(r) (ketoconazole, USP) Gel, 2%, for seborrheic dermatitis; Vusion(r) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis; and Solage(r) (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. Barrier Therapeutics has other product candidates in various stages of clinical development for the treatment of a range of dermatological conditions, including onychomycosis, psoriasis, acne, skin allergies, and superficial fungal infections. The company is headquartered in Princeton, New Jersey and has wholly-owned subsidiaries in Geel, Belgium. More information about Barrier Therapeutics can be found on its corporate website at: www.barriertherapeutics.com.
Xolegel, Vusion and Solage are trademarks of Barrier Therapeutics, Inc.
CONTACT: Barrier Therapeutics, Inc.
Anne M. VanLent, EVP & CFO
(609) 945-1202
Lazar Partners Ltd.
Investor Relations
Gregory Gin
(212) 867-1762
